Other Information
−Removed: During the three months ended September 27, 2025, none of our directors or officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock.
+Added: During the three months ended December 27, 2025, none of our directors or officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock.
Exhibit Number Description
9 unchanged sentences
D'Arecca, Executive Vice President, Chief Financial Officer of the Company.
−Removed: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended September 27, 2025 formatted in inline Extensible Business Reporting Language (XBRL) includes:
+Added: 101* The following materials from Haemonetics Corporation on Form 10-Q for the quarter ended December 27, 2025 formatted in inline Extensible Business Reporting Language (XBRL) includes:
(i) Condensed Consolidated Statements of Income, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statement of Stockholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to Condensed Consolidated Financial Statements.
4 unchanged sentences
HAEMONETICS CORPORATION
−Removed: November 6, 2025 By:
+Added: February 5, 2026 By:
/s/ Christopher A.
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 6, 2025 By:
+Added: February 5, 2026 By:
D’Arecca, Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.